These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 24900535)

  • 1. Hepatitis C virus protease inhibitors: patent highlight.
    Abdel-Magid AF
    ACS Med Chem Lett; 2012 Sep; 3(9):699-700. PubMed ID: 24900535
    [No Abstract]   [Full Text] [Related]  

  • 2. Novel serine protease inhibitors.
    Kore AR; Shanmugasundaram M
    Pharm Pat Anal; 2012 Sep; 1(4):457-68. PubMed ID: 24236883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-HIV antivirals - a review of the recent patent literature.
    Combrink K
    IDrugs; 2002 Aug; 5(8):815-27. PubMed ID: 12802698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in the development of macrocyclic inhibitors of hepatitis C virus NS3-4A protease.
    Avolio S; Summa V
    Curr Top Med Chem; 2010; 10(14):1403-22. PubMed ID: 20536420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitors of hepatitis C--a review of the recent patent literature.
    Zhang X
    IDrugs; 2002 Feb; 5(2):154-8. PubMed ID: 12861476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated plasma concentrations of protease inhibitors and nonnucleoside reverse transcriptase inhibitors in patients coinfected with human immunodeficiency virus and hepatitis B or C: case series and literature review.
    Robertson SM; Scarsi KK; Postelnick MJ; Lynch P
    Pharmacotherapy; 2005 Aug; 25(8):1068-72. PubMed ID: 16207097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct-acting antiviral treatment in adults infected with hepatitis C virus: Reactivation of hepatitis B virus coinfection as a further challenge.
    De Monte A; Courjon J; Anty R; Cua E; Naqvi A; Mondain V; Cottalorda J; Ollier L; Giordanengo V
    J Clin Virol; 2016 May; 78():27-30. PubMed ID: 26967675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protease Inhibitors Block Multiple Functions of the NS3/4A Protease-Helicase during the Hepatitis C Virus Life Cycle.
    McGivern DR; Masaki T; Lovell W; Hamlett C; Saalau-Bethell S; Graham B
    J Virol; 2015 May; 89(10):5362-70. PubMed ID: 25740995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The design of a potent inhibitor of the hepatitis C virus NS3 protease: BILN 2061--from the NMR tube to the clinic.
    Tsantrizos YS
    Biopolymers; 2004; 76(4):309-23. PubMed ID: 15386268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel peptidyl α-aminoalkylphosphonates as inhibitors of hepatitis C virus NS3/4A protease.
    Skoreński M; Pachota M; Pyrć K; Sieńczyk M; Oleksyszyn J
    Antiviral Res; 2017 Aug; 144():286-298. PubMed ID: 28673801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection].
    Hunyady B; Kovács B; Battyáni Z
    Orv Hetil; 2011 Dec; 152(50):1997-2009. PubMed ID: 22112373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The therapeutic approaches for hepatitis C virus: protease inhibitors and polymerase inhibitors.
    Kwo PY; Vinayek R
    Gut Liver; 2011 Dec; 5(4):406-17. PubMed ID: 22195237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of chronic hepatitis C: anticipated impact of resistance in patients treated with protease inhibitors.
    Kronenberger B; Zeuzem S
    Curr Gastroenterol Rep; 2009 Feb; 11(1):15-21. PubMed ID: 19166654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SCREENING OF PROTEASE INHIBITORS RESISTANCE MUTATIONS IN HEPATITIS C VIRUS ISOLATES INFECTING ROMANIAN PATIENTS UNEXPOSED TO TRIPLE THERAPY.
    Dinu S; Calistru PI; Ceauşu E; Târdeil G; Oprişan G
    Roum Arch Microbiol Immunol; 2015; 74(1-2):7-17. PubMed ID: 26727849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The index of ideality of correlation: QSAR studies of hepatitis C virus NS3/4A protease inhibitors using SMILES descriptors.
    Ghiasi T; Ahmadi S; Ahmadi E; Talei Bavil Olyai MR; Khodadadi Z
    SAR QSAR Environ Res; 2021 Jun; 32(6):495-520. PubMed ID: 34074200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of hepatitis C: perspectives.
    Pol S; Corouge M
    Med Mal Infect; 2014 Oct; 44(10):449-54. PubMed ID: 25174659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insights into resistance mechanism of hepatitis C virus nonstructural 3/4A protease mutant to boceprevir using umbrella sampling simulation study.
    Behmard E; Barzegari E
    J Biomol Struct Dyn; 2020 Apr; 38(7):1938-1945. PubMed ID: 31146645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of novel small molecule inhibitors against the NS3/4A protease of hepatitis C virus genotype 4a.
    El-Sayed SM; Ali MAM; El-Gendy BEM; Dandash SS; Issac Y; Saad R; Azab MM; Mohamed MR
    Curr Pharm Des; 2018; 24(37):4484-4491. PubMed ID: 30501598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Diagnosis, treatment, and follow-up of hepatitis C-virus related liver disease. Hungarian national consensus guideline].
    Hunyady B; Gervain J; Horváth G; Makara M; Pár A; Szalay F; Telegdy L; Tornai I
    Orv Hetil; 2014 Mar; 155 Suppl():3-24. PubMed ID: 24631886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peptide inhibitors of hepatitis C virus NS3 protease.
    Portal-Núñez S; González-Navarro CJ; García-Delgado M; Vizmanos JL; Lasarte JJ; Borrás-Cuesta F
    Antivir Chem Chemother; 2003 Sep; 14(5):225-33. PubMed ID: 14694985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.